
Opinion|Videos|June 10, 2025
The Use of Ultra-Low PSA in Specific Patient Profiles
Author(s)Neal Shore, MD, FACS
Research explores the effectiveness of Aerote in treating metastatic hormone-sensitive prostate cancer, focusing on patient subgroups and genetic factors.
Advertisement
Episodes in this series

Patient Selection for Ultra-Low PSA Monitoring
Key Themes:
- Identification of patient profiles most likely to benefit from ultra-low PSA monitoring
- Relevance for specific risk categories
- Potential applications in high-volume disease or triplet therapy
Expert Insights:
- Dr Shore identified specific patient profiles or risk categories where the ultra-low PSA threshold might be particularly valuable.
He discussed its potential relevance for patients with high-volume disease, those receiving triplet therapy, or patients demonstrating rapid initial PSA declines.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Alan Bryce, MD, highlights key phase 3 advances in prostate cancer
2
FDA clears Revi Extend implant for urgency urinary incontinence
3
FDA updates in urology: July 2026
4
FDA grants tentative approval to new cabozantinib capsule formulation
5









